Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer.

Abstract

AIM:

We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer.

MATERIALS & METHODS:

The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.

RESULTS:

Kaplan-Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0.001) and poorer overall survival (p < 0.001). Multivariable Cox analysis further revealed SII as an independent prognostic factor for overall survival (p = 0.010) and progression-free survival (p = 0.001).

CONCLUSION:

SII can serve as a useful biomarker to predict recurrence and death for patients with advanced non-small-cell lung cancer.

• Authors: Dong Guo, Jinbao Zhang, Wang Jing, Jiafeng Liu, Hui Zhu, Lei Fu, Minghuan Li, Li Kong, Jinbo Yue, Jinming Yu
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 25 Pg. 2643-2650 (Oct 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 29747545 (Publication Type: Journal Article)

Chemical References

• Carcinoembryonic Antigen

Topics

• Adult
• Aged
• Aged, 80 and over
• Blood Platelets
• Carcinoembryonic Antigen (blood)
• Carcinoma, Non-Small-Cell Lung (blood, immunology, mortality)
• Female
• Humans
• Inflammation (mortality)
• Lung Neoplasms (blood, immunology, mortality)
• Lymphocytes
• Male
• Middle Aged
• Neutrophils
• Positron Emission Tomography Computed Tomography
• Prognosis
• Proportional Hazards Models
• Retrospective Studies